AZD5153: Clinical Trials

3 trials of AZD5153, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Recruiting 1
Phase 31Recruiting 1

Follow AZD5153: new trials by email Literature Review of AZD5153 trials Research Report on AZD5153

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL
Phase 1CompletedAcerta Pharma BV302018-06-192022-08-15
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AZD5153, Olaparib - Malignant Solid Tumors, Lymphoma
Phase 1CompletedAstraZeneca492017-06-302021-05-06
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis - Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Phase 2 / Phase 3RecruitingBeat AML, LLC30002016-11-012026-09-03

Conditions studied

Breast Neoplasms (1)  ·  Lymphoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Acerta Pharma BV (1)  ·  AstraZeneca (1)  ·  Beat AML, LLC (1)

Countries

United States (3)  ·  Canada (1)  ·  United Kingdom (1)

Top investigators

Alice Mims, MD (1)  ·  Erika P Hamilton, MD (1)  ·  Ian Flinn, MD, PhD (1)

Results publications

PMID 40504618, PMID 40557912

NIH funding

2017 (1)